The All-in-One hair capsule combines the oral versions of Minoxidil and Finasteride, along with Biotin. These ingredients are proven to help improve hair loss. When taken together, their effectiveness is 94%, which is higher than when used individually (83% for Finasteride and 73% for Minoxidil).
Although this treatment isn't yet licensed for hair loss in the UK, it can be prescribed by a qualified clinician after assessing the benefits and risks. Many medications are used off-label, especially in dermatological hair-loss practices. It's important to take the medication as directed, read all the supplied information, and inform us of any changes to your medical history.
How it works:
- Finasteride: This medication tackles the root cause of hair loss by blocking the enzyme 5-alpha reductase (5AR), which converts testosterone into DHT, the androgen responsible for shrinking hair follicles. With less DHT, your hair follicles can recover and produce thicker, stronger hair.
- Minoxidil: Minoxidil increases blood flow and nutrients to your hair follicles, helping each hair strand stay in its growth phase longer, resulting in stronger and thicker hair. Oral Minoxidil is 30% more effective than the topical version because it is absorbed directly into the bloodstream, bypassing the need for the scalp enzyme that activates it.
- Biotin (Vitamin B7): Biotin promotes keratin production, which supports hair growth.
Usage:
- Take ONE tablet DAILY, with or without food. If you miss a dose, do not double up; simply continue with your next dose as normal.
What to Expect:
There's no overnight cure for hair loss, but with patience and consistency, you can see significant improvement. While results may not be immediate, Finasteride and Minoxidil combined are effective in 9 out of 10 men. Hair regrowth could be visible within a few months, with hair loss stabilizing between months 4-6 as the hair cycle resets. By month 8, your hair should be stronger and thicker, with the best results visible past the 12-month mark.
Comments
0 comments
Article is closed for comments.